View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 28, 2022

Boston Scientific reports net sales of $3.03bn in Q1 2022

The company also reorganised its operations into two reportable segments during the quarter.

Boston Scientific’s net sales totalled $3.026bn in the first quarter of 2022, up 10% on a reported basis when compared to $2.75bn recorded in the same period last year.

The figure also represents 12.6% growth on an operational basis and a 9.7% rise on an organic basis.

In the first quarter of 2022, Boston Scientific also reorganised its operations into two reportable segments, namely MedSurg and Cardiovascular. Both units recorded an increase in net sales in the quarter.

However, the US-based company’s GAAP net income available to common stockholders in the quarter dropped to $97m or $0.07 per share (EPS), from $327m or $0.23 per share in the prior-year period.

Boston Scientific chairman and CEO Mike Mahoney said: “Our growth this quarter was fueled by strong execution from our global team, our innovative portfolio and improved procedure volume.

“We are pleased with our first-quarter performance and outlook for the full year, despite the impact of macroeconomic headwinds, and we look forward to bringing meaningful innovation to customers and the patients we serve together.”

In the quarter, Boston Scientific received US Food and Drug Administration (FDA) approval for the EMBOLD Fibered Coil. The fully retractable coil is indicated for arterial and venous embolisation in the peripheral vasculature.

It also received FDA investigational device exemption (IDE) to begin a clinical trial to assess the efficacy of TheraSphere Y-90 Glass Microspheres in patients with recurrent glioblastoma.

Other recent developments include FDA approval for the next-generation Image-Guided Programming Software for Deep Brain Stimulation Therapy and National Medical Products Administration (NMPA) approval in China for Rezūm Water Vapor Therapy for benign prostatic hyperplasia (BPH).

Boston Scientific also completed the acquisition of Baylis Medical Company in the quarter. The deal, signed in October last year, closed in February.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network